UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

(Mark One)

X .

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2014

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______

Commission file number 333-158584

EHOUSE GLOBAL, INC.

(Exact Name of Registrant as Specified in its Charter)

Nevada

57-1221013

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer Identification No.)

9974 Scripps Ranch Blvd. #182

San Diego, CA 92131

(Address of principal executive offices) (Zip Code)

(858) 459-0770

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Securities registered pursuant to Section 12(g) of the Act:

Common Stock, par value $0.001

(Title of class)

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act Yes . No X .

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes . No X .

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X . No .

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. X .

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See definition of “large accelerated filer,” “accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. Check one:


Large accelerated filer	.	Accelerated filer	.
Non-accelerated filer	. (Do not check if a smaller reporting company)	Smaller reporting company	X .

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes . No X .

State the aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant’s most recently completed second fiscal quarter, June 30, 2014: $37,872,432.

At April 15, 2015, 952,920,249shares of the Registrant’s common stock, par value $0.001 per share, were issued and outstanding.

EHOUSE GLOBAL, INC.

TABLE OF CONTENTS



	PART I

ITEM 1	BUSINESS	3

ITEM 1A	RISK FACTORS	8

ITEM 1B	UNRESOLVED STAFF COMMENTS	8

ITEM 2	PROPERTIES	8

ITEM 3	LEGAL PROCEEDINGS	8

ITEM 4	MINE SAFETY DISCLOSURES	8

	PART II

ITEM 5	MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES	8

ITEM 6	SELECTED FINANCIAL DATA	9

ITEM 7	MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS	9

ITEM 7A	QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK	12

ITEM 8	FINANCIAL STATEMENTS	13

ITEM 9	CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE	14

ITEM 9A	CONTROLS AND PROCEDURES	14

ITEM 9B	OTHER INFORMATION	15

	PART III

ITEM 10	DIRECTORS AND EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE	16

ITEM 11	EXECUTIVE COMPENSATION	17

ITEM 12	SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS	18

ITEM 13	CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS AND DIRECTOR INDEPENDENCE	19

ITEM 14	PRINCIPAL ACCOUNTANT FEES AND SERVICES	19

	PART IV

ITEM 15	EXHIBITS AND FINANCIAL STATEMENT SCHEDULES	20

PART I

ITEM 1. BUSINESS

Business Overview

Ehouse Global, Inc. was incorporated under the laws of the Commonwealth of Massachusetts on February 11, 2005 and became a corporation in the State of Nevada on January 7, 2009. The name was changed from Veterans In Packaging, Inc. to Ehouse Global, Inc. (the “Company”) in January 2013.

The Company sold protective packaging solutions for product shipment principally to defense contractors in New England.

We entered into a Share Exchange Agreement effective April 30, 2013 (the “Exchange Agreement”) by and among (i) Ehouse (ii) NutraLiquids, LLC and (iii) the members of NutraLiquids, pursuant to which the holders of 100% of the outstanding units of NutraLiquids transferred to us all the units of NutraLiquids in exchange for the issuance of 52,000,000 shares of our common stock. As a result of the Share Exchange, NutraLiquids became a wholly-owned subsidiary of Ehouse.

As a result of a reverse merger with NutraLiquids and subsequent spinoff of the protective packaging business operations Ehouse ceased to be a company engaged in the commercial packaging market. Ehouse’s operations are now conducted through NutraLiquids and primarily consist of development of and plan to sell liquid nutritional beverages. The merger was accounted for as a reverse acquisition and recapitalization. NutraLiquids is the acquirer for accounting purposes, and Ehouse is the issuer.

Our Current Business

We are a development stage company. Ehouse Global acquires, licenses, and operates companies from around the world that seek distribution in North America. The Company focuses on brands and products that are natural and environmentally focused. The acquisition and licensing model targets products that are highly scalable and provide quantifiable value propositions. Ehouse Global currently has one operating brand; NutraLiquids, which are liquid nutritional supplements.

Nutraliquids includes 16 different liquid nutritional products in single serving pouches with some products also available in 30 day supply, 30 ounce bottles. Each product is named by the vitamins, nutrients, and natural ingredients it contains.

Products

We carry a line of natural liquid dietary aids and nutritional supplements in easy to use, convenient packaging. Our products come in either single-serving pouches or 30 ounce bottles.

Our products include:

Airarmor TM - Natural Herbal Cold & Flu Defense. Lemon-Lime-Tangerine Flavor.

Cal Mag Zinc – Multi-benefit mineral supplement available in Strawberry, Blueberry,

Electric Energy TM – Natural concentrated energy shot. Strawberry- Trioberry Flavor.

Kids Daily TM - Comprehensive daily multivitamin for Children. Orange MangoFlavor

Lemonade Detox – TM – Traditional Lemonade cleansing diet Formula Lemon Flavor.

Liquid Vitamin D3 – Multi-Benefit daily supplement. Cherry Flavor.

LiquidDaily – TM – Comprehensive daily multivitamin for Adults. Pineapple Banana.

Omega369 - Multi-Benefit Vegetarian Omega 3-6-9 complex in Pina Colata Flavor.

PreFade – TM – Natural Hangover prevention. Lemon Lime Tangerine Flavor.

Restera – TM – Natural Sleep Aid. Vanilla Cream Flavor.

Sportflex – TM – Joint health with Antioxident superfruit – Cranapple, Troiberry.

Trimlite – TM – Natural Caffeine-Free Diet Aid / Fat Burner. Tangy Berry Flavor.

To date, we have not produced any revenues and we remain in the developmental stage. Our ability to pursue our business plan and generate any revenues is subject to our ability to obtain additional financing, and we cannot give any assurance that we will be able to do so.

Industry Overview

A study on the dietary supplement industry shows supplement sales of about $32 billion in revenue for just nutritional supplements alone in 2012, and is projected to double, by topping $60 billion in 2021 according to the Nutritional Business Journal. Concerns about health care and aging have led to increased sales in nutritional supplements.

We believe there are several key demographic, healthcare and lifestyle trends driving the continued growth of our industry. These trends include:

Increasing awareness of nutritional supplements across major age and lifestyle segments of the U.S. population. We believe that awareness of the benefits of nutritional supplements is growing among active, younger populations, providing the foundation for our future consumer base. In addition, the average age of the U.S. population is increasing and data from the United States Census Bureau indicates that the number of Americans age 65 or older is expected to increase by approximately 36% from 2010 to 2020. We believe that these consumers are likely to increasingly use nutritional supplements and generally have higher levels of disposable income to pursue healthier lifestyles.

Increased focus on fitness and healthy living. We believe that consumers are trying to lead more active lifestyles and become increasingly focused on healthy living, nutritional and supplemental. According to the Nutrition Business Journal’s 2012 Supplement Business Report, 20% of the U.S. adult population (or 47 million people) were regular or heavy users of vitamins in 2011. We believe that growth in our industry will continue to be driven by consumers who increasingly embrace health and wellness as an important part of their lifestyles.

Participants in our industry include specialty retailers, supermarkets, drugstores, mass merchants, multi-level marketing organizations, online retailers, mail-order companies and a variety of other small participants. The nutritional supplements sold through these channels are divided into four major product categories: vitamins, minerals and health supplements; sports nutrition products; diet products; and other wellness products. Most supermarkets, drugstores and mass merchants have narrow nutrition supplement product offerings limited primarily to simple vitamins and herbs, with less knowledgeable sales associates than specialty retailers.

Competition

The industries in which we operate are highly competitive. Our competition in the beverage industry and nutraceuticals industry includes products owned by multinational corporations with significant financial resources. The energy shot market is dominated by 5-Hour Energy. The key areas of competition are pricing, packaging, development of new products and flavors as well as promotional and marketing strategies. Some of our products compete directly with other emerging recovery shot products. We also indirectly compete with other energy shot products from much larger well-known companies such as 5-Hour Energy, Stacker 2, Hangover Joe’s, and Red Bull. These more established energy shot companies have substantially greater financial, marketing and distribution resources than we do. We also have competitors in the nutritional supplement market. Our largest competitors are MusclePharm, Optimum Nutrition and BSN (Bio-Engineered Supplements and Nutrition), both owned by Glanbia Nutritionals, an international nutritional ingredients group.

Important factors affecting our ability to compete successfully include taste and flavor of products, trade and consumer promotions, rapid and effective development of new, unique cutting edge products, attractive and different packaging, brand exposure and marketing as well as pricing. We also compete for distributors who will give our products more focus than those of our competitors, provide stable and reliable distribution and secure adequate shelf space in retail outlets. Competitive pressures could cause our products to be unable to gain or to lose market share or we could experience price erosion, which could have a material adverse effect on our business and results of operations.

We believe that our product compares favorably with other energy shot products and vitamin supplements because of our superior taste profile, unique packaging and diversity of products. Additionally, we believe that the single serving ready to drink market has been overlooked by many competitors.

Manufacturing and Packaging

We do not directly manufacture our products, but instead outsource the manufacturing process to third party laboratory and co-packing facility. Our co-packaging arrangements are terminable upon notice and do not obligate us to produce any minimum quantities of products within specified periods. Our manufacturer is Innovative Flex Pak. There is no written contract memorializing our relationship.

Marketing Strategy

Our nationwide sales team is already in place and visiting key retailers on a regular basis. This team of sales representatives will promote our new products throughout multiple distribution channels and they provide counsel on the best and most efficient way to maximize store penetration.

NutraLiquids unique position with key retailers applies the feedback we receive directly from the field to better position our products for success.

Direct sales through internet marketing and opt-in email marketing has a huge potential for success with gross profit margins at over 75% which is even higher than our already impressive 64%.

The company has tested internet marketing campaigns through the nations top internet marketing firms such as Adconion Media Group (Formerly Frontline Direct). Adconion is currently serving over 290 million ad impressions per day worldwide and over 50 million daily impressions in the US. They base their platform on advanced techniques such as behavioral targeting, geo-targeting, day-parting, re-targeting, re-search and client side conversion tracking.

Monthly auto-ship programs are very popular with diet and weight-loss programs and our Trimlite product is the perfect vehicle to prove out this model and build a large subscriber base for recurring revenues.

Compliance with Government Regulation

The manufacturing, packaging, labeling, advertising, promotion, distribution and sale of our products are subject to regulation by one or more federal agencies, including the FDA, Consumer Product Safety Commission, or CPSC, and the U.S. Department of Agriculture, or USDA. Advertising and other forms of promotion and methods of marketing are subject to regulation primarily by the U.S. Federal Trade Commission, or FTC, which regulates these activities under the Federal Trade Commission Act, or FTCA. The foregoing matters regarding our products are also regulated by various state and local agencies.

The Dietary Supplement Health and Education Act of 1994, or DSHEA, amended the Federal Food, Drug, and Cosmetic Act, or FFDC Act, to establish a new framework governing the composition, safety, labeling, manufacturing and marketing of dietary supplements. All of the products we market are regulated as dietary supplements under the FFDC Act.

Generally, under the FFDC Act, dietary ingredients that were marketed in the United States prior to October 15, 1994 may be used in dietary supplements without notifying the FDA. “New” dietary ingredients (i.e., dietary ingredients that were “not marketed in the United States before October 15, 1994”) must be the subject of a new dietary ingredient notification submitted to the FDA unless the ingredient has been “present in the food supply as an article used for food” without being “chemically altered”. A new dietary ingredient notification must provide the FDA with evidence of a “history of use or other evidence of safety” establishing that use of the dietary ingredient “will reasonably be expected to be safe”. A new dietary ingredient notification must be submitted to the FDA at least 75 days before it is initially marketed. The FDA may determine that a new dietary ingredient notification does not provide an adequate basis to conclude that the ingredient is reasonably expected to be safe. Such a determination could prevent the marketing of the dietary ingredient. The FDA recently issued draft guidance governing the notification for new dietary ingredients. Although FDA guidance is not mandatory, and companies are free to use an alternative approach if the approach satisfies the requirements of applicable laws and regulations, FDA guidance is a strong indication of the FDA’s “current thinking” on the topic discussed in the guidance, including its position on enforcement. At this time, it is difficult to determine whether the draft guidance, if finalized, would have a material impact on our operations. However, if the FDA were to enforce the applicable statutes and regulations in accordance with the draft guidance as written, this manner of enforcement could require us to incur additional expenses, which could be significant, and negatively impact our business in several ways, including, but not limited to, enjoining the manufacturing of our products until the FDA determines that we are in compliance and can resume manufacturing, which could increase our liability and reduce our growth prospects.

The Dietary Supplement Labeling Act of 2011, which was introduced in July 2011 (S1310), would amend the FFDC Act to, among other things, (i) require dietary supplement manufacturers to register the dietary supplements that they manufacture with the FDA (and provide a list of the ingredients in and copies of the labels and labeling of the supplements), (ii) mandate the FDA and the Institute of Medicine (a non-governmental, nonprofit organization that provides advice to the public and decision makers, such as the FDA, concerning health issues) to identify dietary ingredients that cause potentially serious adverse effects, (iii) require warning statements for dietary supplements containing potentially unsafe ingredients and (iv) require that the FDA define the term “conventional food”. If the bill is reintroduced and enacted, it could restrict the number of dietary supplements available for sale, increase our costs, liabilities and potential penalties associated with manufacturing and selling dietary supplements, and reduce our growth prospects.

The Dietary Supplement Safety Act (S3002) was introduced in February 2010 and would repeal the provision of DSHEA that permits the sale of all dietary ingredients sold in dietary supplements marketed in the United States prior to October 15, 1994, and instead permit the sale of only those dietary ingredients included on a list of Accepted Dietary Ingredients to be issued and maintained by the FDA. The bill also would allow the FDA to: impose a fine of twice the gross profits earned by a distributor on sales of any dietary supplement found to violate the law; require a distributor to submit a yearly report on all non-serious adverse event reports received during the year to the FDA; and allow the FDA to recall any dietary supplement it determines with “a reasonable probability” would cause serious adverse health consequences or is adulterated or misbranded. The bill also would require any dietary supplement distributor to register with the FDA and submit a list of the ingredients in and copies of the labels of its dietary supplements to the FDA and thereafter update such disclosures yearly and submit any new dietary supplement product labels to the FDA before marketing any dietary supplement product. If this bill is reintroduced and enacted, it could severely restrict the number of dietary supplements available for sale and increase our costs and potential penalties associated with selling dietary supplements.

The FDA or other agencies could take actions against products or product ingredients that in its determination present an unreasonable health risk to consumers that would make it illegal for us to sell such products. In addition, the FDA could issue consumer warnings with respect to the products or ingredients in such products at the point they are sold to end users. Such actions or warnings could be based on information received through FFDC Act mandated reporting of serious adverse events. The FDA in recent years has applied these procedures to require that consumers be warned to stop using certain dietary supplements. For businesses that have been subjected to these regulatory actions, sales have been reduced and the businesses have been required to pay refunds for recalled products.

In general, we seek representations and warranties, indemnification and/or insurance from our vendors. However, even with adequate insurance and indemnification, any claims of non-compliance could significantly damage our reputation and consumer confidence in our products. In addition, the failure of such products to comply with applicable regulatory and legislative requirements could prevent us from marketing the products or require us to recall or remove such products from the market, which in certain cases could materially and adversely affect our business, financial condition and results of operations.

Under the current provisions of the FFDC Act, there are four categories of claims that pertain to the regulation of dietary supplements. First are health claims that describe the relationship between a nutrient or dietary ingredient and a disease or health related condition and can be made on the labeling of dietary supplements if supported by significant scientific agreement and authorized by the FDA in advance via notice and comment rulemaking. Second are nutrient content claims which describe the nutritional value of the product and may be made if defined by the FDA through notice and comment rulemaking and if one serving of the product meets the definition. Third are statements of nutritional support or product performance. The FFDC Act permits “statements of nutritional support” to be included in labeling for dietary supplements without FDA pre-market approval. These statements must be submitted to the FDA within 30 days of marketing and may describe how a particular dietary ingredient affects the structure, function or general well-being of the body, or the mechanism of action by which a dietary ingredient may affect body structure, function or well-being, but may not expressly or implicitly represent that a dietary supplement will diagnose, cure, mitigate, treat or prevent a disease. A company that uses a statement of nutritional support in labeling must possess scientific evidence substantiating that the statement is truthful and not misleading. The fourth category are drug claims, representations that a product is intended to diagnose, mitigate, treat, cure or prevent a disease, are prohibited from use in the labeling of dietary supplements, and we make no drug claims regarding our products.

We may make claims for our dietary supplement products regarding three of the four categories, that are statements of nutritional support, health claims and nutrient content claims when authorized by the FDA, or that otherwise are allowed by law. The FDA’s interpretation of what constitutes an acceptable statement of nutritional support may change in the future, thereby requiring that we revise our labeling. These regulatory activities include those discussed above concerning products marketed before October 15, 1994 or afterwards, and the requirements of 75 days advance notice to the FDA before marketing products containing new dietary ingredients. There is no assurance that the FDA will accept the evidence of safety for any new dietary ingredients that we may wish to market, and the FDA’s refusal to accept that evidence could prevent the marketing of the new dietary ingredients and dietary supplements containing a new dietary ingredient. If the FDA determines that a particular statement of nutritional support is an unacceptable drug claim, conventional food claim or an unauthorized version of a “health claim”, or, if the FDA determines that a particular claim is not adequately supported by existing scientific data or is false or misleading, we would be prevented from using the claim.

In addition, DSHEA provides that so-called “third-party literature”, e.g., a reprint of a peer-reviewed scientific publication linking a particular dietary ingredient with health benefits, may be used “in connection with the sale of a dietary supplement to consumers” without the literature being subject to regulation as labeling. The literature: (1) must not be false or misleading; (2) may not “promote” a particular manufacturer or brand of dietary supplement; (3) must present a balanced view of the available scientific information on the subject matter; (4) if displayed in an establishment, must be physically separate from the dietary supplements; and (5) should not have appended to it any information by sticker or any other method. If the literature fails to satisfy each of these requirements, we may be prevented from disseminating such literature with our products, and any dissemination could subject our product to regulatory action as an illegal drug. Our dietary supplements must also comply with the Dietary Supplement and Nonprescription Drug Consumer Protection Act, which became effective on December 22, 2007. This law amends the FFDC Act to mandate that we report to the FDA any reports of serious adverse events that we receive. Under the law, an “adverse event” is any health-related event associated with the use of a dietary supplement that is adverse, and a “serious adverse event” is any adverse event that results in death, a life-threatening experience, inpatient hospitalization, a persistent or significant disability or incapacity, or a congenital anomaly or birth defect, or requires, based on reasonable medical judgment, a medical or surgical intervention to prevent one of these outcomes. Serious adverse event reports received through the address or phone number on the label of a dietary supplement, as well as all follow-up reports of new medical information received within one year after the initial report, must be submitted to the FDA no later than 15 business days after the report is received. The law also requires recordkeeping for reports of non-serious adverse events as well as serious adverse events for six years following the event, and these records are subject to FDA inspection.

As a result of our efforts to comply with applicable statutes and regulations in the United States and elsewhere, we have from time to time reformulated, eliminated or relabeled certain of our products and revised certain advertising claims. We cannot predict the nature of any future laws, regulations, interpretations or applications, nor can we determine what effect additional governmental regulations or administrative orders, when and if promulgated, would have on our business in the future. They could, however, require the reformulation of certain products to meet new standards, the recall or discontinuance of certain products not capable of reformulation, additional record keeping, expanded documentation of the properties of certain products, expanded or different labeling, and/or scientific substantiation. Any or all of such requirements could have a material adverse effect on our business, financial condition and results of operations.

Advertising and labeling for dietary supplements and conventional foods are also regulated by state, county and other local governmental authorities. Some states also permit these laws to be enforced by private attorney generals. These private attorney generals may seek relief for consumers, seek class action certifications, seek class-wide damages, seek class-wide refunds and product recalls of products sold by us. There can be no assurance that state and local authorities will not commence regulatory action, which could restrict the permissible scope of our product advertising claims, or products that can be sold in the future.

Possible New Legislation or Regulation

Legislation may be introduced which, if passed, would impose substantial new regulatory requirements on dietary supplements. For example, although not yet reintroduced in this session of Congress, bills have been repeatedly proposed in past sessions of Congress which would subject the dietary ingredient dehydroepiandrosterone, or DHEA, to the requirements of the Controlled Substances Act, which would prevent the sale of products containing DHEA. In March 2009, the General Accounting Office, or GAO, issued a report that made four recommendations to enhance the FDA’s oversight of dietary supplements. The GAO recommended that the Secretary of the Department of Health and Human Services direct the Commissioner of the FDA to: (1) request authority to require dietary supplement companies to identify themselves as a dietary supplement company and update this information annually, provide a list of all dietary supplement products they sell and a copy of the labels and update this information annually, and report all adverse events related to dietary supplements, not just serious adverse events; (2) issue guidance to clarify when an ingredient is considered a new dietary ingredient, the evidence needed to document the safety of new dietary ingredients, and appropriate methods for establishing ingredient identity; (3) provide guidance to industry to clarify when products should be marketed as either dietary supplements or conventional foods formulated with added dietary ingredients; and (4) coordinate with stakeholder groups involved in consumer outreach to identify additional mechanisms for educating consumers about the safety, efficacy, and labeling of dietary supplements, implement these mechanisms, and assess their effectiveness. These recommendations could lead to increased regulation by the FDA or future legislation concerning dietary supplements.

We cannot determine what effect additional domestic or international governmental legislation, regulations, or administrative orders, when and if promulgated, would have on our business in the future. New legislation or regulations may require the reformulation of certain products to meet new standards, require the recall or discontinuance of certain products not capable of reformulation, impose additional record keeping or require expanded documentation of the properties of certain products, expanded or different labeling or scientific substantiation.

Employees

The Company currently has two employees, Scott Corlett and Dace Corlett.

ITEM 1A. RISK FACTORS

Smaller reporting companies are not required to provide the information required by this item.

ITEM 1B. UNRESOLVED STAFF COMMENTS

Smaller reporting companies are not required to provide the information required by this item.

ITEM 2. PROPERTIES

The Company does not own any property and rents space on an as-needed basis. Because the Company outsources most of its operations, the need for space is infrequent.

ITEM 3. LEGAL PROCEEDINGS

We are currently not involved in any litigation that we believe could have a materially adverse effect on our financial condition or results of operations. There is no action, suit, proceeding, inquiry, or investigation pending or to the knowledge of the executive officers of our Company.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

PART II

Public Market for Common Stock

Our common stock has been trading on the OTCBB under the symbol EHOS. OTCBB is a quotation service that displays real-time quotes, last-sale prices, and volume information in over-the-counter, or the OTC, equity securities. An OTCBB equity security generally is any equity that is not listed or traded on a national securities exchange. The following table shows, for the periods indicated, the high and low bid prices per share of our common stock as reported by the OTCBB quotation service. These bid prices represent prices quoted by broker-dealers on the OTCBB quotation service. The quotations reflect inter-dealer prices, without retail mark-up, markdown or commissions, and may not represent actual transactions.

Price range of common stock

The following table shows, for the periods indicated, the high and low bid prices per share of our common stock as reported by the OTCBB quotation service. These bid prices represent prices quoted by broker-dealers on the OTCBB quotation service. The quotations reflect inter-dealer prices, without retail mark-up, mark-down or commissions, and may not represent actual transactions.


	High	Low
Quarter Ended December 31, 2014	$0.07	$0.01
Quarter Ended September 30, 2014	$0.28	$0.06
Quarter Ended June 30, 2014	$2.10	$0.22
Quarter Ended March 31, 2014	$0.06	$0.01

Quarter Ended December 31, 2013	$0.30	$0.05
Quarter Ended September 30, 2013	$0.30	$0.30
Quarter Ended June 30, 2013	-	-
Quarter Ended March 31, 2013	-	-

Holders

As of April 15, 2015, there were 24 stockholders of record holding an aggregate of shares of the company’s common stock. This does not reflect the number of persons or entities who held stock in nominee or street name through various brokerage firms.

Dividends

We have not declared or paid any cash dividends on our common stock, and we do not anticipate declaring or paying cash dividends for the foreseeable future. We are not subject to any legal restrictions respecting the payment of dividends, except that we may not pay dividends if the payment would render us insolvent. Any future determination as to the payment of cash dividends on our common stock will be at our board of directors’ discretion and will depend on our financial condition, operating results, capital requirements and other factors that our board of directors considers to be relevant.

Securities Authorized for Issuance under Equity Compensation Plans

We presently do not have any equity based or other long-term incentive programs. In the future, we may adopt and establish equity-based or other long-term incentive plan if it is in the best interest of the Company and the stockholders to do so.

Recent Sales of Unregistered Securities

On March 18, 2014, the Company issued an aggregate of 500,000 shares of Series A Preferred Stock to Mr. Scott Corlett, the Company’s President, Chief Executive Officer, Secretary and Treasurer, in consideration for services rendered to the Company, including for and as incentive to continue to assist and provide services to the Company. As a holder of outstanding shares of Series A Preferred Stock, Mr. Corlett is entitled to five hundred (500) votes for each share of Series A Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

On November 3, 2014, the Company issued an aggregate of 100,000 shares of Series B Preferred Stock to Mr. Scott Corlett, the Company’s President, Chief Executive Officer, Secretary and Treasurer, in consideration for services rendered to the Company, including for and as incentive to continue to assist and provide services to the Company. As a holder of outstanding shares of Series B Preferred Stock, Mr. Corlett is entitled to one million (1,000,000) votes for each share of Series B Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

The shares of preferred stock described above were not registered under the Securities Act of 1933 and are restricted securities. The shares were issued pursuant to the registration exemption afforded the Company under Section 4(2) of the Securities Act due to the fact that Mr. Corlett is the Chief Executive Officer and a Director of the Company. Mr. Corlett acquired these shares for his own accounts. The certificates representing these shares will bear a restricted legend providing that they cannot be sold except pursuant to an effective registration statement or an exemption from registration.

ITEM 6 – SELECTED FINANCIAL DATA

Smaller reporting companies are not required to provide the information required by this item.

ITEM 7 – MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The following discussion should be read in conjunction with the financial statements and notes thereto appearing elsewhere in this Form 10-K. The following discussion contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 relating to future events or our future performance. Actual results may materially differ from those projected in the forward-looking Statements as a result of certain risks and uncertainties set forth in this prospectus. Although management believes that the assumptions made and expectations reflected in the forward- looking statements are reasonable, there is no assurance that the underlying assumptions will, in fact, prove to be correct or that actual results will not be different from expectations expressed in this report.

Our Business

Ehouse acquires or licenses brands from around the world that seek distribution in North America. The Company focuses on brands and products that are natural and environmentally-focused. The acquisition and licensing model targets products that are highly scaleable and provide quantifiable value propositions. The team is comprised of senior executives and industry experts in Manufacturing, PR, Sales, Distribution and Logistics. Ehouse Global Inc. currently has one operating brand: NutraLiquids, which are liquid nutritional supplements. Operations are currently are now conducted through NutraLiquids and primarily consist of development of and plan to sell liquid nutritional beverages. NutraLiquids develops nutraceutical vitamin, supplement and functional beverage products for the consumer packaged goods industry. The Company develops unique products based on natural ingredients with packaging for the general retail market. The Company’s products target online retailers, grocery stores, pharmacies, convenience stores and big box retailers. The Company has developed all of its products internally and has many years of experience in liquid vitamin and supplement experience. The company develops unique products like Restera, an all-natural sleep support product and AirArmour, a natural immunity support product. The products are packaged in retail ready boxes which can be simply opened and placed on store shelves and register counters. The company has introduced 16 nutraceutical products using natural ingredients packaged in single serving ready to drink pouches and 30 ounce 30 day supply bottles.

Recent Developments

Stock Splits

The Company declared a 34 for 1 forward split of its common stock in January 2013. All share and per share amounts in this prospectus thereto give retroactive effect to the forward split.

On November 21, 2014, the Company filed an Information Statement on Form 14C informing shareholders that it has received shareholder and board member consent to effectuate a 1-100 reverse stock split. The Company effectuated the split on December 30, 2014.

Investment Agreement with Dutchess

On January 23, 2014, we entered into an investment agreement with Dutchess Opportunity Fund, II, LP, a Delaware limited partnership (“Dutchess”). Pursuant to the terms of the Dutchess Investment Agreement, Dutchess committed to purchase up to $10,000,000 of our common stock over a period of up to thirty-six (36) months. From time to time during the thirty-six (36) months period commencing from the effectiveness of the registration statement, we may deliver a put notice to Dutchess which states the dollar amount that we intend to sell to Dutchess on a date specified in the put notice. The Put Amount shall be equal to up to either 1) two hundred percent (200%) of the average daily volume (U.S. market only) of the Common Stock for the three (3) Trading Days prior to the applicable Put Notice Date, multiplied by the average of the three (3) daily closing prices immediately preceding the Put Date or 2) on hundred thousand dollars ($100,000). The purchase price per share to be paid by Dutchess shall be calculated at a ten percent (10%) discount to the lowest volume weighted average price of the common stock as reported by Bloomberg, L.P. during the five (5) consecutive trading days immediately after the receipt by Dutchess of the put notice. We initially reserved 244,500,000 shares of our common stock for issuance under the Dutchess Investment Agreement.

In connection with the Dutchess Investment Agreement, we also entered into a registration rights agreement with Dutchess, pursuant to which we are obligated to file a registration statement with the Securities and Exchange Commission (the “SEC”) covering 244,500,000 shares of our common stock underlying the Dutchess Investment Agreement within 21 days after the closing of the transaction. In addition, we are obligated to use all commercially reasonable efforts to have the registration statement declared effective by the SEC and maintain the effectiveness of such registration statement until termination of the Dutchess Investment Agreement.

The Dutchess Investment Agreement is not transferable and any benefits attached thereto may not be assigned.

Increase in Authorized Shares

On March 19, 2014, the Company filed an amendment to the Company’s articles of incorporation with the Secretary of State of the State of Nevada, to increase the Company’s authorized common stock from two hundred fifty million (250,000,000) shares of common stock, par value $0.001 per share, to seven hundred fifty million (750,000,000) shares of common stock, par value $0.001 per share.

On June 25, 2014, the Company filed an amendment to the Company’s articles of incorporation with the Secretary of State of the State of Nevada, to increase the Company’s authorized common stock from two seven hundred fifty million (750,000,000) shares of common stock, par value $0.001 per share, to two billion, five hundred million (2,500,000,000) shares of common stock, par value $0.001 per share.

On December 15, 2014, the Company filed an amendment to the Company’s articles of incorporation with the Secretary of State of the State of Nevada, to increase the Company’s authorized common stock from two billion, five hundred million (2,500,000,000) shares of common stock, par value $0.001 per share, to five billion (5,000,000,000) shares of common stock, par value $0.001 per share.

Issuance of Series A Preferred Stock and Series B Preferred Stock

On March 18, 2014, the Company determined that it was in the best interests of the Company to file a Certificate of Designation that authorized the issuance of up to five hundred thousand (500,000) shares of a new series of preferred stock, par value $ 0.001 per share, designated “Series A Preferred Stock” for which the Board of Directors established the rights, preferences and limitations thereof. Each share of Series A Preferred Stock has voting rights of 500 votes per share. All 500,000 shares were issued to Scott Corlett for services rendered.

On November 3, 2014, the Company determined that it was in the best interests of the Company to file a Certificate of Designation that authorized the issuance of up to one hundred thousand (100,000) shares of a new series of preferred stock, par value $ 0.001 per share, designated “Series B Preferred Stock” for which the Board of Directors established the rights, preferences and limitations thereof. Each share of Series B Preferred Stock has voting rights of 1,000,000 votes per share. All 100,000 shares were issued to Scott Corlett for services rendered.

Reverse Merger and Spinoff

We entered into a Share Exchange Agreement effective April 30, 2013 by and among (i) Ehouse (ii) NutraLiquids and (iii) the shareholders of NutraLiquids, pursuant to which the holders of 100% of the outstanding units of NutraLiquids transferred to us all of the units of NutraLiquids in exchange for the issuance of 52,000,000 shares of our common stock. As a result of the Share Exchange, NutraLiquids became a wholly-owned subsidiary of Ehouse.

The merger was accounted for as a reverse acquisition and recapitalization. NutraLiquids is the acquirer for accounting purposes, and Ehouse is the issuer. Accordingly, NutraLiquids' historical financial statements for periods prior to the acquisition become those of the acquirer retroactively restated for the equivalent number of shares issued in the merger. Reported operations prior to the merger are those of NutraLiquids. No Ehouse operating results from prior to the merger date are included in reported financial statements of operations. Earnings per share for the period prior to the merger are restated to reflect the equivalent number of shares outstanding.

We entered into a Spin-off Agreement with Ed Peplinski, our former President and largest shareholder, under which we assigned and transferred to Mr. Peplinski all of our rights, title and interest in and to the operating assets specifically associated with its packaging business sand assumed the liabilities specifically associated with the packaging business as defined in the Spin-off Agreement and return 198,000,000 shares of our common stock owned by him.

As a result of the Spin-off Agreement, we ceased to be a company engaged in the commercial packaging market. Our operations are now conducted through NutraLiquids and primarily consist of development of and plan to sell liquid nutritional beverages.

The Company cannot take advantage of being an emerging growth company under the JOBS Act because it had gone public prior to December 8, 2011.

Results of Operations

Operating Expenses

Operating costs were incurred in the amount of $1,217,779 and $211,246 in 2014 and 2013, respectively. The operating expenses increased significantly as our operations expanded and we prepared for roll out of our newly developed products.

Other Income and Expense

Other income and expense was primarily financing costs including interest and amounted to $1,562,671 and $51,517 in 2014 and 2013, respectively.

Net Loss

The Company had a net loss in the amount of $2,780,450 in 2014, compared to a net loss of $262,763 in 2013.

Liquidity and Capital Resources

The Company has $907 of cash on hand as of December 31, 2014. We currently have very limited cash to continue operations for twelve months.

We intend to rely upon the issuance of common stock and loans and advances from shareholders to fund administrative expenses pending acquisition of an operating company. However, our shareholders are under no obligation to provide such funding, and there can be no assurance that any of the contemplated financing arrangements described herein will be available and if available, can be obtained on favorable terms to the Company.

As discussed above, the Company had a net loss of $2,780,450 for the year ended December 31, 2014. The Company also had a stockholder’s deficiency of $1,082,282 and a working capital deficiency of $1,058,931 as of December 31, 2014. As noted in the report of our independent registered Certified Public Accountants, this raises substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern has been, and remains, dependent on advances from its stockholders and the Company’s ability to raise additional capital. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

Critical Accounting Policies

Our significant accounting policies are summarized in Note 1 of our financial statements included in this annual report on Form 10-K for the year ended December 31, 2014. Our financial statements and related public financial information are based on the application of accounting principles generally accepted in the United States (“GAAP”). GAAP requires the use of estimates, assumptions, judgments and subjective interpretations of accounting principles that have an impact on the assets, liabilities, revenues and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures including information regarding contingencies, risk and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made during the preparation of our financial statements.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements.

Contractual Obligations

We do not have any contractual obligations.

ITEM 7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

Smaller reporting companies are not required to provide the information required by this item.

ITEM 8 - FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA

EHOUSE GLOBAL, INC

FINANCIAL STATEMENTS

TABLE OF CONTENTS


Contents	Page

Reports of Independent Registered Public Accounting Firms	F-1

Balance Sheets as of December 31, 2014 and 2013	F-3

Statements of Operations for the Years Ended December 31, 2014 and 2013	F-4

Statements of Stockholder’s Equity for the Years Ended December 31, 2014 and 2013	F-5

Statements of Cash Flows for the years Ended December 31, 2014 and 2013	F-6

Notes to the Financial Statements	F-7

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Ehouse Global, Inc. dba NutraLiquids

San Diego, CA 92131

We have audited the accompanying Balance Sheets of Ehouse Global, Inc. dba NutraLiquids as of December 31, 2014, and the related statements of operations, stockholder’s deficit, and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based upon our audit.

In our opinion, such financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2014 and the results of its operations and its cash flows for the year then ended, in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raises substantial doubt about its ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

/s/ RBSM, LLP

Houston, TX

April 14, 2015

F-1

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and Stockholders

Ehouse Global, Inc. dba NutraLiquids

(Formerly Veterans in Packaging, Inc. a developmental company)

San Diego, CA 92131

We have audited the accompanying balance sheets of Ehouse Global, Inc. dba NutraLiquids (the “Company”) as of December 31, 2013, and the related statements of operations, stockholders’ deficit, and cash flows for the year then ended. These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audit included consideration of internal control over financial reporting as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion. An audit also includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, as well as evaluation the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2013, and the results of its operations and its cash flows for the year then ended in conformity with accounting principles generally accepted in the United States of America.

The accompanying financial statements have been prepared on a going concern basis which contemplates the realization of assets and satisfaction of liabilities in the normal course of business. As discussed in Note 3 to the Company’s financial statements, the Company has an accumulated deficit of $2,926,843, a working capital deficiency of $1,058,931 and no source of debt or equity financing. These factors raise substantial doubt about the Company’s ability to continue as a going concern which is dependent upon the Company’s ability to achieve profitable operations or obtain adequate financing. The financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.

L.L. Bradford & Company

/s/ L.L. Bradford & Company

Houston, Texas

May 15, 2014

F-2

EHOUSE GLOBAL, INC.

dba Nutraliquids

Balance Sheets



					December 31,		December 31,
					2014		2013
ASSETS
Current Assets
	Cash			$	907	$	14,779
	Prepaid expenses				-		5,664
	Investment receivable				-		-
	Debt Issuance Costs				3,972		3,122
		Total Current Assets			4,879		23,565
		Furniture and Equipment net of depreciation			935		-
			Total Assets	$	5,813	$	23,565
LIABILITIES
Current Liabilities
	Accounts payable & accrued expenses			$	55,031	$	30,600
	Notes Payable				-		100,000
	Notes Payable - related party				75,000		75,000
	Convertible Debt, Net of debt discount of $ 75,117 and $ 46,399 respectively				384,592		6,601
	Derivative Liability - Warrants				24,826		-
	Derivatives Liability				524,361		89,372
			Total current liabilities		1,063,810		301,573
	Convertible Debt, Net of debt discount of $ 51,846 and $ 0 respectively				24,285		-
			Total Liability		1,088,095		301,573
STOCKHOLDERS' DEFICIT
Stockholders' Deficit
Preferred Stock : $0.001 par value, 1,000,000 shares authorized, 600,000 and 0 issued and outstanding					600		-
Common stock: $ 0.001 par value, 5,000,000,000 shares authorized; 13,095,733 and 998,000 shares issued and outstanding at December 31, 2014 and December 31, 2013					13,096		998
Additional paid- in capital					2,082,280		118,802
Accumulated deficit					(3,178,258)		(397,808)
		Total Stockholders' deficit			(1,082,282)		(278,008)
		Total liabilities and stockholders’ deficit		$	5,813	$	23,565
The accompanying notes are an integral part of these Financial Statements.

F-3

EHOUSE GLOBAL, INC.

dba Nutraliquids

Statement of Operations


			December 31,		December 31,
			2014		2013
Operating expenses:
	General and administrative expenses	$	1,217,779	$	211,246
	Total operating expenses		1,217,779		211,246
Other ( Income ) Expense:
	Interest expense		745,577		15,145
	Derivative interest expense		1,226,180		91,346
	Change in fair value of derivatives liabilities		(409,086)		(54,974)
	Total other ( Income) expense		1,562,671		51,517
Net loss before taxes			(2,780,450)		(262,763)
Income taxes			-		-
Net Income (Loss)		$	(2,780,450)	$	(262,763)
Net Income ( Loss ) per common share : Basic and Diluted		$	(0.61)	$	(0.27)

Weighted average number of common shares outstanding: Basic and Diluted			4,555,561		991,333
The accompanying notes are an integral part of these Financial Statements

F-4


EHOUSE GLOBAL, INC.
dba Nutraliquids
Statement of change in Stockholders Equity(Deficit)
	Preferred Stock			Common Stock				Additional Paid - in		Accumulated
	Preferred Stock			Common Stock				Additional Paid - in		Accumulated
	Shares		Amount	Shares		Amount		Capital		(Deficit)		Total
Balance, January1,2013	-	$	-	988,000	$	988	$	117,812	$	(135,045)	$	(16,245)
Issuance of in connection with Senior Note	-		-	10,000		10		990		-		1,000
Net loss	-		-	-		-		-		(262,763)		(262,763)
Balances, December 31, 2013	-		-	998,000		998		118,802		(397,808)		(278,008)
Preferred Stock Issued for services	600,000		600	-		-		441,946		-		442,546
Common stock issued for services	-		-	5,000		5		62,495		-		62,500
Derivative liability associated with change conversion	-		-	-		-		1,050,166		-		1,050,166
Common stock issued to sell	-		-	400,000		400		22,127		-		22,527
Convertible debt and accrued interest converted into common stock	-		-	11,692,733		11,693		386,744		-		398,437
Net Loss	-		-	-		-		-		(2,780,450)		(2,780,450)
Balances, December 31, 2014	600,000	$	600	13,095,733	$	13,096	$	2,082,280	$	(3,178,258)	$	(1,082,282)
The accompanying notes are an integral part of these Financial Statements

F-5

EHOUSE GLOBAL, INC.

dba Nutraliquids

Statements of Cash Flows



		December 31		December 31
		2014		2013
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Income ( Loss )	$	(2,780,450)	$	(262,763)
Adjustments to reconcile Net ( Loss) to Net Cash
Used in operating activities :
Depreciation expense		245		-
Stock Based Compensation		505,046		-
Amortization of debt offering costs and debt discount		675,876		7,479
Derivative interest expense		1,226,180		91,346
Change in fair value of derivative liabilities		(409,086)		(54,974)
Change in operating assets and liabilities :
Prepaid expenses and other current assets		5,664		2,706
Accounts payable and accrued expenses		41,141		4,379
Net Cash Used in Operating Activities		(735,384)		(211,827)
CASH FROM INVESTING ACTIVITIES
Purchase of Equipment		(1,180)		-
Net cash provided by investing activities		(1,180)		-
CASH FROM FINANCING ACTIVITIES-
Proceeds from sale of common stock		22,527		-
Proceeds from note payable		-		100,000
Proceeds from related party		-		75,000
Direct offering costs paid		(22,250)		(3,000)
Issuance of Convertible Notes Payable		722,415		53,000
Net Cash provided by Financing Activities		722,692		225,000
CHANGE IN CASH		(13,872)		13,173
CASH AT BEGINNING OF PERIOD		14,779		1,606
CASH AT END OF PERIOD	$	907	$	14,779
Supplementary disclosure of non-cash financing activity:
Non-cash additions to convertible note balance	$	5,000	$	-
Reclassification of derivative liability to additional paid in capital	$	1,050,166	$	-
Note payable reclassified to convertible debt	$	100,000	$	-
Shares issued in conversion of convertible debt and accrued interest	$	398,437	$	-
Debt discount on convertible note accounted for as a derivative liability	$	730,040	$	53,000
Issuance of shares in connection with loan	$	-	$	1,000
Supplementary disclosure of cash flow information
Cash paid during the period for:
Interest	$	-	$	-
Income taxes	$	-	$	-
The accompanying notes are an integral part of these Financial Statements

F-6

Ehouse Global, Inc.

dba NutraLiquids

December 31, 2014 and 2013

Notes to Financial Statements

NOTE 1 - ORGANIZATION

Ehouse Global, Inc. was incorporated under the laws of the Commonwealth of Massachusetts on February 11, 2005, and became a corporation in the State of Nevada on January 7, 2009. It changed its name to Ehouse Global, Inc. (the “Company”) in January, 2013.

Reverse Merger and Spinoff

The merger was accounted for as a reverse acquisition and recapitalization. NutraLiquids is the acquirer for accounting purposes, and Ehouse is the issuer. Accordingly, NutraLiquids’ historical financial statements for periods prior to the acquisition become those of the acquirer retroactively re-stated for the equivalent number of shares issued in the merger. Reported operations prior to the merger are those of NutraLiquids. No E House operating results from prior to the merger date are included in the reported financial statements of operations.

Earnings per share for the period prior to the merger are restated to reflect the equivalent number of shares outstanding.

We entered into an Assignment and Assumption Agreement (the “Spin-off Agreement” ) with Edward Peplinski, the former President and largest stockholder of Veterans in Packaging, Inc, under which we assigned and transferred to Mr. Peplinski all of our rights, title, and interest in and to the operating assets specifically associated with its packaging business and assumed the liabilities specifically associated with the packaging business as defined in the Agreement and returned 198,000,000 shares of our common stock owned by him.

The Company cannot take advantage of being an emerging growth company under the JOBS Act because it had gone public prior to December 8, 2011.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NutraLiquids develops nutraceutical vitamin, supplement and functional beverage products for the consumer packaged goods industry.

Basis of Presentation

Our financial statements include the accounts of E House Global, Inc. and have been prepared in accordance with accounting principles generally accepted in the United States of America. (“U.S. GAAP”).

Impact of New Accounting Standards

The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations.

Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

F-7

Fair Value of Financial Instruments

The Company measures assets and liabilities at fair value based on expected exit price as defined by the authoritative guidance on fair value measurements, which represents the amount that would be received on the sale date of an asset or paid to transfer a liability, as the case may be, in an orderly transaction between market participants. As such, fair value may be based on assumptions that market participants would use in pricing an asset or liability. The authoritative guidance on fair value measurements establishes a consistent framework for measuring fair value on either a recurring or nonrecurring basis whereby inputs, used in valuation techniques, are assigned a hierarchical level.

The following are the hierarchical levels of inputs to measure fair value:

Level 1: Observable inputs that reflect quoted prices (unadjusted) for identical assets or liabilities in active markets.

Level 2: Inputs reflect quoted prices for identical assets or liabilities in markets that are not active; quoted prices for similar assets or liabilities in active markets; inputs other than quoted prices that are observable for the assets or liabilities; or inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3: Unobservable inputs reflecting the Company’s assumptions incorporated in valuation techniques used to determine fair value. These assumptions are required to be consistent with market participant assumptions that are reasonably available.

The carrying amounts of the Company’s financial assets and liabilities, such as cash, accounts payable and accrued expenses, approximate their fair values because of the current nature of these instruments. Debt approximates fair value based on interest rates available for similar financial arrangements. Derivative liabilities which have been bifurcated from host convertible debt agreements are presented at fair value.

The following is the major category of liabilities measured at fair value on a recurring basis as of December 31, 2014, using quoted prices in active markets for identical liabilities (Level 1); significant other observable inputs (Level 2); and significant unobservable inputs (Level 3):


Derivative Liabilities from Convertible Notes (Level 3)	$	524,359
Derivative Liabilities from Convertible Note Warrants (Level 3)		24,826
Total	$	549,185

Debt offering costs and debt discount

The Company may pay debt issue costs, and record debt discounts in connection with raising funds through the issuance of convertible debt. These costs are amortized to interest expense over the life of the debt. If a conversion of the underlying debt occurs, a proportionate share of the unamortized amounts is immediately expensed.

Income Taxes

The Company accounts for income taxes using the asset and liability method under FASB Accounting Standards Codification (ASC) Section 740-1-30. Deferred income tax assets and liabilities are provided for based upon differences between financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance to the extent management concludes it is more likely than not that the assets will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in the statements of operations in the period that includes the enactment date.

Derivative Financial Instruments

Fair value accounting requires bifurcation of embedded derivative instruments such as convertible features in convertible debts or equity instruments, and measurement of their fair value for accounting purposes. In determining the appropriate fair value, the Company uses the binomial option-pricing model. In assessing the convertible debt instruments, management determines if the convertible debt host instrument is conventional convertible debt and further if these is a beneficial conversion feature requiring measurement. If the instrument is not considered conventional convertible debt, the Company will continue its evaluation process of these instruments as derivative financial instruments.

F-8

Once determined, derivative liabilities are adjusted to reflect fair value at each reporting period end, with any increase or decrease in the fair value being recorded in results of operations as an adjustment to fair value of derivatives. In addition, the fair value of freestanding derivative instruments, such as warrants, are also valued using the binomial option-pricing model.

Original issue discount

For certain convertible debt issued, the Company provides the debt holder with an original issue discount. The original issue discount is recorded to debt discount, reducing the face amount of the note and is amortized to interest expense over the life of the debt.

Commitments and Contingencies

The Company follows FASB ASC 450-20 of the FASB Accounting Standards Codification to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Net Income (Loss) Per Common Share

Basic Net Income (loss) per common share is computed pursuant to FASB ASC 260-10-45. Basic net loss per share is computed by dividing net loss by the weighted average number of shares of common stock outstanding during the period. Diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock and potentially outstanding shares of common stock during each period.

Subsequent Events

The Company follows the guidance in FASB ASC 855-10-50 for the disclosure of subsequent events. The Company evaluates subsequent events from the date of the balances sheet through the date when the financial statements are issued or available to be issued.

NOTE 3 – GOING CONCERN

The accompanying financial statements have been prepared assuming that we will continue as a going concern. As reflected in the accompanying financial statements, we have very limited financial resources, with working capital and net shareholder deficits and had not generated any revenue through December 31, 2014.

We have actively developed and plan to introduce sixteen different liquid nutritional products into the market. While we are undertaking our business plan to generate additional revenues, our cash position may not be sufficient to support our basic business plan and product distribution efforts. Management believes that the actions presently underway to introduce our products to the marketplace have a realistic chance of succeeding. While we believe in the viability of our strategy to increase revenues and in our ability to achieve profitable results, there can be no assurances to that effect. Our ability to continue as a going concern is dependent upon our ability to raise additional funds, but there can be no assurances to that effect. Our ability to continue as a going concern is dependent upon our ability to achieve profitable operations or obtain adequate financing.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. These financial statements do not include any adjustments relating to the recovery of the recorded assets or the classification of the liabilities that might be necessary should the Company be unable to continue as a going concern.

F-9

NOTE 4 - INCOME TAXES

We have experienced losses since inception and have a net operating loss for federal income tax purposes of approximately $2,055,594. A net deferred tax asset resulting from this loss carry forward in the approximate amount of $699,000 has been offset by a valuation allowance in the same amount based upon our assessment of the probability of its realization.

Our net operating loss expires according to the following schedule:


Year Ending December 31,		Amount
2031	$	105,512
2032		29,533
2033		214,637
2034		1,705,912
Total	$	2,055,594

NOTE 5 - CONVERTIBLE DEBT

On various dates from November 27, 2013 through September 3, 2014, the Company issued convertible promissory notes totaling $934,081.Of this amount, $53,000 was recorded during the year ended December 31, 2013, and $881,081 was recorded during the year ended December 31, 2014. At the time of issuance, the notes were evaluated and were determined to contain embedded conversion options that are required to bifurcated and reported at fair value and original issue discounts. As a result, a discount on convertible promissory notes was recorded, net of discount amortization for the year ended December 31, 2014 amounted to $126,963.


Description		12/31/2014		12/31/2013
18 convertible promissory notes in amounts ranging from $25,000 to $113,654, with maturity dates ranging from 2014 to August 2016, bearing interest ranging from 0% to 12% per annum, convertible into common stock at variable conversion prices ranging from 25% of the lowest price in the prior 20 trading days to 60% of the lowest price in the prior 25 trading days.	$	934,081	$	53,000
Conversions		(398,241)		-
Unamortized portion of discount		(126,963)		(46,399)
Net	$	408,877	$	6,601

Debt Issue Costs

During the year ended December 31, 2014 and 2013, the Company paid debt issue costs totaling $22,250 and $4,000, which includes non-cash additions of $5,000 during the year ended December 31, 2014 and fees paid through the issuance of common stock in the amount of $1,000 during the year ended December 31, 2013, respectively.

The following is a summary of the Company’s debt issue costs:


	Year ended		Year ended
	December 31, 2014		December 31, 2013

Debt issue costs	$	26,250	$	4,000
Accumulated amortization of debt issue costs		(22,278)		(878)
Debt issue costs - net	$	3,972	$	3,122

F-10

Debt Discount

During the year ended December 31, 2014 and the year ended December 31, 2013, the Company recorded debt discounts totaling $730,956 and $53,000, respectively.

The debt discount recorded pertains to convertible debt that contains embedded conversion options that are required to bifurcated and reported at fair value and original issue discounts.

The Company amortized $650,392 and $6,601 during the year ended December 31, 2014 and 2013, respectively, to amortization of debt discount expense.


	As of		As of
	December 31, 2014		December 31, 2013

Debt discount	$	783,956	$	53,000
Accumulated amortization of debt discount		(656,993)		(6,601)
Debt discount - net	$	126,963	$	46,399

Derivative Liabilities

The Company identified conversion features embedded within this convertible debt. The Company has determined that the features associated with the embedded conversion option should be accounted for at fair value as a derivative liability.

As a result of the application of ASC No. 815, the fair value of the conversion feature is summarized as follow:


Derivative liability - December 31, 2012	$	-
Fair value at the commitment date for convertible instruments		144,346
Change in fair value of embedded derivative liability		(54,974)
Derivative liability - December 31, 2013		89,372

Add Fair value at the commitment date for convertible notes issued during 2014		1,902,462
Reclassification of derivative liability associated with convertible debt that ceased being a derivative liability to additional paid in capital		(1,033,652)
Fair value mark to market adjustment for convertible debt		(408,997)
	$	549,185

The Company recorded the debt discount to the extent of the gross proceeds raised, and expensed immediately the remaining value of the derivative as it exceeded the gross proceeds of the note. The Company recorded a derivative expenses for the year ended December 31, 2014 and 2013 of 1,226,180and 91,346, respectively.

The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of December 31, 2014:


Assumption	Commitment Date	Remeasurement Date

Expected dividends:	0%	0%
Expected volatility:	352.71% - 415.16%	28.23% - 744.33%
Expected term (years):	0.5 - 2 years	0.0082 - 1.57 years
Risk free interest rate:	0.09% - .13%	0.03% - 0.25%

F-11

The fair value at the commitment and re-measurement dates for the Company’s derivative liabilities were based upon the following management assumptions as of December 31, 2013:


Assumption	Commitment Date	Remeasurement Date
Expected dividends:	0%	0%
Expected volatility:	391%	371%
Expected term (years):	0.75	0.65
Risk free interest rate:	0.13%	0.13%

NOTE 6 - DEBT TO RELATED PARTY

The Company’s President has made a loan of $ 75,000 to the Company. The loan is interest-free and due upon demand.

NOTE 7 - STOCKHOLDERS EQUITY

Common Stock

The share exchange agreement between NutraLiquids, LLC as the accounting acquirer and Ehouse as the legal acquirer effective April 30, 2013 resulted in the retroactive recognition of the common stock issuance of Ehouse on inception of the business on December 14, 2010.

On May 3, 2012, the Company received a $20,000 contribution to capital from an existing shareholder for no additional shares.

On July 19, 2013, the Company issued 1,000,000 shares of common stock in connection with an agreement with a finance corporation to actively seek additional financing for the Company. As there was no active trading market for the Company’s shares, the share issuance was reflected at par value of $1,000.

On March 19, 2014, the Company entered into a consulting agreement for the consultant to provide the Company general consulting services which would include financing introductions, business development opportunities and general marketing activities. In connection with this agreement, during year ended 2014, the Company issued 5000 shares values at $ 62,500. The fair value of the stock issuance was based upon the quoted closing price on the date of issuance.

In September of 2014, the Company issued 400,000 shares of common stock for cash in the amount of $22,127.

Throughout the year ended December 31, 2014, the company issued shares of common stock totaling 11,692,733 shares in conversion of convertible debt.

Series A Preferred Shares

On March 18, 2014, the Board of Directors of Ehouse Global, Inc. (the “Company”) determined that it was in the best interests of the Company to file a Certificate of Designation that authorized the issuance of up to five hundred thousand (500,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series A Preferred Stock” for which the Board of Directors established the rights, preferences and limitations thereof. The Board of Directors authorized the Series A Preferred Stock pursuant to the authority given in the Articles of Incorporation, which authorizes the issuance of up to two hundred fifty one million (251,000,000) shares of authorized stock, par value $0.001 per share, and authorizes the Board, by resolution, to establish any or all of the unissued shares of preferred stock, not then allocated to any series into one or more series and to fix and determine the designation of each such shares, the number of shares which shall constitute such series and certain preferences, limitations and relative rights of the shares of each series so established. The Certificate of Designation was filed as an amendment to the Articles of Incorporation with the State of Nevada on March 18, 2014.

Each holder of outstanding shares of Series A Preferred Stock shall be entitled to five hundred (500) votes for each share of Series A Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

The summary of the rights, privileges, and preferences of the Series A Preferred Stock described above is qualified in its entirety by reference to the Articles of Amendment, a copy of which is attached as Exhibit 3.1 to this report and is incorporated herein by reference.

F-12

Series B Preferred Shares

On November 3, 2014, the Board of Directors of Ehouse Global, Inc. (the “Company”) determined that it was in the best interests of the Company to file a Certificate of Designation that authorized the issuance of up to one hundred thousand (100,000) shares of a new series of preferred stock, par value $0.001 per share, designated “Series B Preferred Stock” for which the Board of Directors established the rights, preferences and limitations thereof. The Board of Directors authorized the Series B Preferred Stock pursuant to the authority given in the Articles of Incorporation, which authorizes the issuance of up to two billion five hundred million (2,500,000,000) shares of authorized stock, par value $0.001 per share, and authorizes the Board, by resolution, to establish any or all of the unissued shares of preferred stock, not then allocated to any series into one or more series and to fix and determine the designation of each such shares, the number of shares which shall constitute such series and certain preferences, limitations and relative rights of the shares of each series so established.

Each holder of outstanding shares of Series B Preferred Stock shall be entitled to one million (1,000,000) votes for each share of Series B Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

The summary of the rights, privileges, and preferences of the Series B Preferred Stock described above is qualified in its entirety by reference to the Articles of Amendment, a copy of which is attached as Exhibit 3.1 to this report and is incorporated herein by reference.

Amendment to Articles of Incorporation

Unregistered Sale of Equity Securities

On March 18, 2014, the Company issued an aggregate of 500,000 shares of Series A Preferred Stock to Mr. Scott Corlett, the Company’s President, Chief Executive officer, Secretary and Treasurer, in consideration for services rendered to the Company, including for and as incentive to continue to assist and provide services to the Company. As a holder of outstanding shares of Series A Preferred Stock, Mr. Corlett is entitled to five hundred (500) votes for each share of Series A Preferred Stock held on the record date for the determination of stockholders entitled to vote at each meeting of stockholders of the Company.

F-13

NOTE 8 – SUBSEQUENT EVENT

As disclosed in the Current Report on Form 8-K, filed on March 11, 2015, the Company entered into a Settlement Agreement and Stipulation Agreement (the “Settlement Agreement”) with IBC Funds, LLC, a Nevada limited liability company (“IBC”) pursuant to which the Company agreed to issue common stock to IBC in exchange for the settlement of $85,827.93 (the “Settlement Amount”) of past-due accounts payable of the Company. IBC purchased the accounts payable from certain vendors of the Company.

On March 6, 2015, the Circuit Court of the Twelfth Judicial Circuit in and for Manatee County, Florida (the “Court”), entered an order (the “Order”) approving, among other things, the fairness of the terms and conditions of an exchange pursuant to Section 3(a)(10) of the Securities Act of 1933, as amended (the “Securities Act”), in accordance with a stipulation of settlement, pursuant to the Settlement Agreement between the Company and IBC, in the matter entitled IBC Funds, LLC v. Ehouse Global, Inc. (the “Action”). IBC commenced the Action against the Company to recover an aggregate of $85,827.93 of past-due accounts payable of the Company (the “Claim”), which IBC had purchased from certain vendors of the Company pursuant to the terms of separate receivable purchase agreements between IBC and each of such vendors. The Order provides for the full and final settlement of the Claim and the Action. The Settlement Agreement became effective and binding upon the Company and IBC upon execution of the Order by the Court on March 7, 2015.

Pursuant to the terms of the Settlement Agreement approved by the Order, on March 7, 2015, the Company agreed to issue to IBC shares (the “Settlement Shares”) of the Company’s common stock, $0.001 par value (the “Common Stock”). The Settlement Agreement provides that the Settlement Shares will be issued in one or more tranches, as necessary, sufficient to satisfy the Settlement Amount through the issuance of freely trading securities issued pursuant to Section 3(a) (10) of the Securities Act. Pursuant to the Settlement Agreement, IBC may deliver a request to the Company which states the dollar amount of Common Stock to be issued to IBC. The parties agree that the total amount of Common Stock to be delivered by the Company to satisfy the share request shall be issued at a 50% discount to market based upon the average of the volume weighted average price of the Common Stock over the 20 trading day period preceding the share request. Additional tranche requests shall be made as requested by IBC until the Settlement Amount is paid in full so long as the number of shares requested does not make IBC the owner of more than 9.99% of the outstanding shares of Common Stock at any given time.

The Company has evaluated all events that occurred after the balance sheet date of December 31, 2014, through April 10, 2015, the date that these financial statements were available to be issued.

F-14

ITEM 9 - CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

The Financial Statements for the year ended December 31, 2013, and were included in our Form 10K filing, included a Report from the Independent Accounting Firm of LL Bradford LLP that had an unqualified opinion and no disagreements over accounting matters. Prior to the audit of our Financial Statements for the year ended December 31, 2014, we were informed that the firm of LL Bradford LLP had merged with the firm of RBSM, LLP and that the Independent, Registered, Accounting Firm that would be issuing the opinion on our Financial Statements would be under the name RBSM, LLP, from their Houston, TX office. We approved the engagement of RBSM, LLP to perform the audit, and we have no accounting disagreements with them. They have issued their unqualified opinion on the fairness of our Financial Statements in accordance with generally accepted accounting principles.

ITEM 9A – CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time period specified in the Securities and Exchange Commission's rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed under the Exchange Act is accumulated and communicated to management, including our president (our principal executive officer, principal financial officer and principal accounting officer) as appropriate to allow timely decisions regarding required disclosure.

We carried out an evaluation, under the supervision and with the participation of our management, including our president (our principal executive officer, principal financial officer and principal accounting officer), of the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2014. Based upon the evaluation of our disclosure controls and procedures as of the June 30, 2014, our president (our principal executive officer, principal financial officer and principal accounting officer) concluded that our disclosure controls and procedures were not effective because of the identification of a material weakness in our internal control over financial reporting which is identified below, which we view as an integral part of our disclosure controls and procedures.

Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Rule 13a-15(f). Our internal control over financial reporting is a process designed by, or under the supervision of, our principal executive and principal financial officer, and effected by our board of directors, to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America.

Our internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of our assets; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with accounting principles generally accepted in the United States of America, and our receipts and expenditures of are being made only in accordance with authorizations of our management and directors; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of our assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal controls over financial reporting may not prevent or detect misstatements. All internal control systems, no matter how well designed, have inherent limitations, including the possibility of human error and the circumvention of overriding controls. Accordingly, even effective internal control over financial reporting can provide only reasonable assurance with respect to financial statement preparation. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Company’s management assessed the effectiveness of the Company’s internal control over financial reporting as of June 30, 2014. In making this assessment, the Company used the criteria set forth in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission in 1992 (“COSO”). Based upon our evaluation under the framework in Internal Control-Integrated Framework, our management concluded that our internal control over financial reporting were not effective as of June 30, 2014.

Management has determined that, as of the December 31, 2014 measurement date, there were deficiencies in both the design and the effectiveness of our internal control over financial reporting. Management has assessed these deficiencies and determined that there were various material weaknesses in our internal control over financial reporting. The existence of a material weakness or weaknesses is an indication that there is a more than remote likelihood that a material misstatement of our financial statements will not be prevented or detected in a future period.

The material weakness relates to the lack of segregation of duties in our financial reporting process and our utilization of outside third party consultants. We do not have a separately designated audit committee. This weakness is due to our lack of sufficient working capital to hire additional staff. To remedy this material weakness, we intend to engage an internal accounting staff to assist with financial reporting as soon as our finances will allow.

Changes in Internal Control

During the period covered by this report, there were no changes in our internal controls over financial reporting that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

ITEM 9B - OTHER INFORMATION

Consulting Agreement

On January 25, 2014, the Company signed an investor relations service agreement with the Circadian Group (the “Service Provider”) pursuant to which the Company engages the Service Provider to provide investor relations services for an initial twelve (12) month period commencing on the date of the agreement. The Company agreed to pay the Service Provider at least $2,500 per month in exchange for a variety of investor services. These services include, but are not limited to: (1) press releases, website and all other media creation and consultation, (2) email newsletter blasting to the Service Provider’s investor list, (3) shareholder identification, survey and tracking model analysis and consultation and (4) update and input accurate fundamental corporate data into identified financial outlets. The total amount paid to the Service Provider was $90,475 as of December 31, 2014.

Settlement Agreement

PART III

ITEM 10 – DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

The following chart lists all the Officers of the Company, their respective ages and positions with the Company as of December 31, 2014.


Name	Age	Position
Scott Corlett	51	Chairman and President
Dace Corlett	46	Director
Michael Murray	67	Director

Scott Corlett – Chief Executive Officer, Chief Financial Officer and Chairman of the Board

In his 29 years as a senior executive, Scott Corlett has led companies in roles of President, CEO, and Chairman of the Board. He has spent the past five years developing the NutraLiquids brand. He has raised millions of dollars for companies to drive rapid growth and position themselves as market leaders. Scott has built multiple companies to national and international distinction, from angel and venture funded startups to becoming the leading provider in each of the various marketplaces with hundreds of employees worldwide, all while positioning the company as the model of corporate integrity. In 1997, he sold one of his companies to a public company, creating one of the most notable publicly traded companies in its industry. Corlett’s vision and business acumen have made him one of the most influential and widely quoted serial entrepreneurs. His leadership and determination enable organizations to outpace their peers, to grow while others have collapsed, to leverage market opportunities in good economies and bad, and to claim the leadership mantle as the greatest companies un their space. Corlett is a YPO member and graduated from MIT’s Birthing of Giants Program in 2001. He is an avid marathoner and swimmer.

Dace Corlett

Dace Corlett attended the California Culinary Academy and has since built on her culinary foundation to include studies on nutritional therapies and nutrition related illness. Believing that poor nutrition is the root of most modern day disease, she strives to help people eat a more nutrient dense diet and leverage the use of good quality supplements to balance their diets and help to compensate for nutritional deficiencies. Dace’s current studies will allow her to develop even more compelling supplements for NutraLiquids. Her background and experience in the nutritional field will be an asset to the Board.

Michael Murray – Director

Michael Murray is a Certified Public Accountant with over thirty-five years of experience working in corporate accounting with companies large and small. Mr. Murray has been a Senior Accountant at Detroit Edison, The Smith Group, Quintiles, The First American Corporation, and Comerica Bank. From 1982 to 1988 Mr. Murray was a Consultant for the Royal family in Saudi Arabia in London, Switzerland, and Riyadh, serving on the Board of International Associates, planning the entire country of Saudi Arabia. Since 2003, Mr Murray has been self-employed for Murray & Associates LLC serving individuals and small business Clients, developing internal controls, computer systems, forming Corporations, LLCs, and filing Tax Returns and SEC filings. Mr. Murray has worked closely with Mr. Corlett since the inception of NutraLiquids.

Term of Office

Our Directors are appointed for one year terms to hold office until the next annual general meeting of shareholders or until removed from office in accordance with our by-laws. Our officers are appointed by our board of directors and hold office until removed by the board.

Family Relationships

Mr. Scott Corlett is married to Ms. Dace Corlett.

Involvement in Certain Legal Proceedings

To our knowledge, during the past ten (10) years, none of our directors, officers, promotors, control persons, or nominees has been:

the subject of any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer at the time of the bankruptcy or within two years prior to that time;

convicted in a criminal proceeding or is subject to a pending criminal proceeding (excluding traffic violations and other minor violations);

subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his involvement in any type of business, securities, or banking activities; or

found by a court of competent jurisdiction (in a civil action) the Commission or the Commodity Futures Trading Commission to have violated a federal or state securities law or commodities law.

Code of Ethics

In 2013, we adopted a Code of Ethics and Business Conduct which is applicable to our future employees and which also includes a Code of Ethics for our CEO and principal financial officers and persons performing similar functions. A code of ethics is a written standard designed to deter wrongdoing and to promote:

honest and ethical conduct,

full, fair, accurate, timely and understandable disclosure in regulatory filings and public statements,

compliance with applicable laws, rules, and regulations,

the prompt reporting of violations of the code, and

accountability for adherence to the code.

Board Committees

Our Board of Directors has no separate committees and our Board of Directors acts as the audit committee and the compensation committee.

ITEM 11. EXECUTIVE COMPENSATION

Compensation of Executive Officers

The following summary of compensation sets forth all compensation awarded to, earned by, or paid to the named executive officers paid by us during the fiscal years ended December 31, 2014 and 2013 in all capacities for the accounts of our executives:


Name and principal position	Year	Salary	Bonus	Stock Awards	Option Awards	Non-Equity Incentive Plan	Nonqualified Deferred Compensation Earnings	All Other Compensation	Total
Scott Corlett, CEO	2014	$210,000	-	$442,546 (1)	-	-	-	-	$652,546
Scott Corlett, CEO	2013	-	-	-	-	-	-	-	-

(1)

Mr. Corlett was issued 500 shares of Series A Preferred Stock and 100 shares of Series B Preferred Stock as of December 31, 2014. These shares are valued at $442,546.

There is no employment contract with Mr. Corlett at this time; nor are there any agreements for compensation in the future. Mr. Corlett’s compensation has not been fixed or based upon any percentage calculations. He has made all the decisions determining the amount and timing of his compensation and has received the level of compensation each month that permitted us to meet our obligations.

No retirement, pension, profit sharing, stock option or insurance programs or similar programs have been adopted by us for the benefit of our employees. We had no options outstanding as of December 31, 2014.

Compensation of Directors

Directors are permitted to receive fixed fees and other compensation for their services as directors. The Board of Directors has the authority to fix the compensation of directors. $85,000 has been paid to, or accrued to, directors in such capacity.

Employment Agreements

We do not have any employment agreements with our officers or directors currently.

Outstanding Equity Awards as of Fiscal Year End

There are no equity awards outstanding at December 31, 2014.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDERS

Beneficial ownership is determined in accordance with the rules of the SEC. Generally, a person is considered to beneficially own securities: (i) over which such person, directly or indirectly, exercises sole or shared voting or investment power, and (ii) of which such person has the right to acquire beneficial ownership at any time within 60 days ( such as through exercise of stock options or warrants ). For purposes of computing the percentage of outstanding shares held by each person or group of persons, any shares that such person or persons has the right to acquire within 60 days of March 31, 2015, are deemed to be outstanding, but are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person. The inclusion herein of any shares listed as beneficially owned does not constitute an admission of beneficially owned does not constitute an admission of beneficial ownership. Unless otherwise indicated below, the address of each person listed below is: c/o 9974 Scripps Ranch Blvd. # 182 San Diego, CA 92131.


	Amount and Nature of Beneficial Ownership of Common Stock		Percent of Common Stock (1)			Amount and Nature of Beneficial Ownership of Preferred Stock		Percent of Preferred Stock (2)
Directors and Executive Officers
Scott Corlett, Chairman and President		300,429,000		31.2	%		600,000		100	%
Dace Corlett, Director(3)		300,429,000		31.2	%		600,000		100	%
Michael Murray, Director		52,000		*	%		-		-
All directors and officers as a group (4 people)		300,481,000		31.5	%		600,000		100	%

(1) Based on 952,920,249 shares of common stock issued and outstanding as of April 15, 2015.

(2) Based upon 500,000 shares of Series A Preferred stock and 100,000 shares of Series B preferred stock issued and outstanding as of March 31, 2015. Each share of Series A Preferred Stock has voting rights of 500 votes per share. Each share of Series B Preferred Stock has voting rights of 1,000,000 votes per share. The total aggregate number of votes the Series A Preferred Stock and Series B Preferred Stock is 100,250,000,000.

(3) Dace Corlett is the wife and beneficial owner of all stock issued to Scott Corlett.

* Less than 1%

Except as noted below, there have been no transactions in which the amount involved exceeds the lesser of $120,000 or one percent of the average of the Company’s total assets at year end for the last two completed fiscal years.

The Company’s President has made a loan of $ 75,000 to the Company. The loan is interest-free and due upon demand.

Director Independence

Because our common stock is not currently listed on a national securities exchange, we have used the definition of “independence” of The NASDAQ Stock Market to make this determination. NASDAQ Listing Rule 5605(a)(2) provides that an “independent director” is a person other than an officer or employee of the Company or any other individual having a relationship which, in the opinion of the Company’s board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The NASDAQ listing rules provide that a director cannot be considered independent if:

the director is, or at any time during the past three years was, an employee of the Company;

the director or a family member of the director accepted any compensation from the Company in excess of $120,000 during any period of 12 consecutive months within the three years preceding the independence determination (subject to certain exclusions, including, among other things, compensation for board or board committee service);

a family member of the director is, or at any time during the past three years was, an executive officer of the Company;

the director or a family member of the director is a partner in, controlling stockholder of, or an executive officer of an entity to which the Company made, or from which the Company received, payments in the current or any of the past three fiscal years that exceed 5% of the recipient’s consolidated gross revenue for that year or $200,000, whichever is greater (subject to certain exclusions);

the director or a family member of the director is employed as an executive officer of an entity where, at any time during the past three years, any of the executive officers of the Company served on the compensation committee of such other entity; or the director or a family member of the director is a current partner of the Company’s outside auditor, or at any time during the past three years was a partner or employee of the Company’s outside auditor, and who worked on the Company’s audit.

We do not have any independent directors.

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

Audit Fees

For the Company’s fiscal year years ended December 31, 2014 and 2013 we were billed $52,048 and $14,870 for professional services rendered for the audit and reviews of our financial statements.

Audit Related Fees

The Company did not incur any audit related fees, other than the fees discussed in Audit Fees, above for services related to our audit for the fiscal years ended December 31, 2014 and 2013.

Tax Fees

For the Company’s fiscal years ended December 31, 2014 and 2013, we were not billed for professional services rendered for tax compliance, tax advice, or tax planning.

All Other Fees

The Company did not incur any other fees related to services rendered by our principal accountant for the fiscal years ended December 31, 2014 or December 31, 2013.

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

Effective May 6, 2003, the Securities and Exchange Commission adopted rules that require that before our auditor is engaged by us to render any auditing or permitted non-audit related service, the engagement be:

approved by our audit committee; or

entered into pursuant to pre-approved policies and procedures established by the audit committee, provided the policies and procedures are detailed as to the particular service, the audit committee is informed of each service, and such policies and procedures do not include delegation of the audit committee’s responsibilities to management.

We do not have an audit committee. Our entire board of directors pre-approves all services provided by our independent auditors. All of the above services and fees were reviewed and pre-approved by the entire board of directors before the respective services were rendered.

PART IV

ITEM 15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

a) Documents filed as part of this Annual Report

1. Financial Statements

2. Financial Statement Schedules

3. Exhibits


Exhibit
No.	Description
3.1	Articles of Incorporation (1)
3.2	Amendment to Articles of Incorporation (2)
3.3	Amendment to the Articles of Incorporation,
3.4	Certificate of Designation for Series B Preferred Stock*
3.5	Bylaws (1)
23.1	Consent of L. L. Bradford & Company, LLC *
101.INS	XBRL Instance Document
101.SCH	XBRL Taxonomy Extension Schema Document
101.CAL	XBRL Taxonomy Extension Calculation Linkbase Document.
101.LAB	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE	XBRL Taxonomy Extension Presentation Linkbase Document.
101.DEF	XBRL Taxonomy Extension Definition Linkbase Document.

__________________________________

* Filed herein.

(1)

Incorporated herein by reference to the registration statement on Form S-1 filed with the SEC on April 15, 2009.

(2)

Incorporated herein by reference to the current report on Form 8-K filed with the SEC on March 27, 2014.

(3)

Incorporated herein by reference to the annual report on Form 10-K filed with the SEC on April 15, 2014.

(4)

Incorporated herein by reference to the current report on Form 8-K filed with the SEC on July 18, 2013.

(5)

Incorporated herein by reference to the current report on Form 8-K filed with the SEC on July 17, 2013.

(6)

Incorporated herein by reference to the annual report on Form 10-K filed with the SEC on April 15, 2014 and the quarterly report on Form 10-Q filed with the SEC on May 20, 2014.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized:

EHOUSE GLOBAL, INC.

By: /s/ Scott Corlett

Chief Executive Officer

(Duly Authorized Officer, and Principal Executive Officer and Interim Principal Financial Officer)

Dated April 15, 2015

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.


Name	Title	Date

/s/Scott Corlett	President, CEO, Principal Executive	April 15, 2015
Scott Corlett	Officer, Interim Principal Financial Officer
and Principal Accounting Officer

/s/ Dace Corlett	Director	April 15, 2015
Dace Corlett

/s/ Michael Murray	Director	April 15, 2015
Michael Murray

EHOUSE GLOBAL, INC. 10-K